scholarly journals Association between bone marrow fluorodeoxyglucose uptake and recurrence after curative surgical resection in patients with T1–2N0M0 lung adenocarcinoma: a retrospective cohort study

2020 ◽  
Vol 10 (12) ◽  
pp. 2285-2296
Author(s):  
Tian-Cheng Li ◽  
Li-Li Wang ◽  
Bo-Le Liu ◽  
Jun-Jie Hong ◽  
Ni-Na Xu ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cohort Study ◽  
Lung Adenocarcinoma ◽  
Surgical Resection ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort

scholarly journals Occupational radiation and haematopoietic malignancy mortality in the retrospective cohort study of US radiologic technologists, 1983–2012

2020 ◽  
Vol 77 (12) ◽  
pp. 822-831
Author(s):  
Martha S Linet ◽  
Mark P Little ◽  
Cari M Kitahara ◽  
Elizabeth K Cahoon ◽  
Michele M Doody ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cohort Study ◽  
Radiation Dose ◽  
Dose Response ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Radiologic Technologists ◽  
Mortality Risks ◽  
Baseline Questionnaire ◽  
Occupational Radiation

ObjectivesTo evaluate cumulative occupational radiation dose response and haematopoietic malignancy mortality risks in the US radiologic technologist cohort.MethodsAmong 110 297 radiologic technologists (83 655 women, 26 642 men) who completed a baseline questionnaire sometime during 1983–1998, a retrospective cohort study was undertaken to assess cumulative, low-to-moderate occupational radiation dose and haematopoietic malignancy mortality risks during 1983–2012. Cumulative bone marrow dose (mean 8.5 mGy, range 0–430 mGy) was estimated based on 921 134 badge monitoring measurements during 1960–1997, work histories and historical data; 35.4% of estimated doses were based on badge measurements. Poisson regression was used to estimate excess relative risk of haematopoietic cancers per 100 milligray (ERR/100 mGy) bone-marrow absorbed dose, adjusting for attained age, sex and birth year.ResultsDeaths from baseline questionnaire completion through 2012 included 133 myeloid neoplasms, 381 lymphoid neoplasms and 155 leukaemias excluding chronic lymphocytic leukaemia (CLL). Based on a linear dose-response, no significant ERR/100 mGy occurred for acute myeloid leukaemia (ERR=0.0002, 95% CI <−0.02 to 0.24, p-trend>0.5, 85 cases) or leukaemia excluding CLL (ERR=0.05, 95% CI <−0.09 to 0.24, p-trend=0.21, 155 cases). No significant dose-response trends were observed overall for CLL (ERR<−0.023, 95% CI <−0.025 to 0.18, p-trend=0.45, 32 cases), non-Hodgkin lymphoma (ERR=0.03, 95% CI <−0.2 to 0.18, p-trend=0.4, 201 cases) or multiple myeloma (ERR=0.003, 95% CI −0.02 to 0.16, p-trend>0.5, 112 cases). Findings did not differ significantly by demographic factors, smoking or specific radiological procedures performed.ConclusionAfter follow-up averaging 22 years, there was little evidence of a relationship between occupational radiation exposure and myeloid or lymphoid haematopoietic neoplasms.

Adjuvant Gamma Knife radiosurgery following surgical resection of brain metastases: a 9-year retrospective cohort study

2009 ◽  
Vol 98 (1) ◽  
pp. 77-82 ◽  
Author(s):  
Steven W. Hwang ◽  
Mohab M. Abozed ◽  
Andrew Hale ◽  
Rebecca L. Eisenberg ◽  
Tomas Dvorak ◽  
...  
Keyword(s):  
Cohort Study ◽  
Brain Metastases ◽  
Surgical Resection ◽  
Gamma Knife ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Gamma Knife Radiosurgery

scholarly journals Adherence to colonoscopy at 1 year following resection of localized colon cancer: a retrospective cohort study

2018 ◽  
Vol 11 ◽  
pp. 175628481876592 ◽  
Author(s):  
Alfred I. Neugut ◽  
Xiaobo Zhong ◽  
Benjamin Lebwohl ◽  
Grace C. Hillyer ◽  
Melissa K. Accordino ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cohort Study ◽  
Surgical Resection ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Large Population ◽  
Tumor Stage ◽  
Population Based ◽  
Surveillance Colonoscopy ◽  
Clinical Factors

Background: For patients with stages I-III colon cancer who have undergone surgical resection, guidelines recommend surveillance colonoscopy at 1 year. However, limited data exist on adherence and associated factors. We aimed to determine the rate of adherence to surveillance colonoscopy at 1 year among nonmetastatic colon cancer patients who underwent resection and factors associated with adherence. Methods: In this population-based retrospective cohort study, the Surveillance, Epidemiology, and End Results (SEER)–Medicare database was used. We identified patients with stages I-III colon cancer who underwent surgical resection and survived >3 years without recurrence (no chemotherapy after 8 months) from 2002–2011. Our primary outcome was a colonoscopy claim 10–15 months after resection. We used multivariable regression analysis to assess associations between sociodemographic and clinical factors and receipt of timely colonoscopy. Results: Among 28,732 patients who survived >3 years without recurrence, 7967 (28%) did not undergo colonoscopy; 12,033 (42%) had it at one year, with 3159 (11%) before 10 months and 5573 (19%) after 15 months. Decreased adherence was associated with older age; being male versus female; being black or Hispanic versus white; higher tumor stage; left-sided tumors versus right sided; and increased comorbidities. Chemotherapy receipt was associated with increased adherence (odds ratio 2.06; 95% confidence interval 1.88–2.24). Conclusions: In a large population-based sample of individuals aged ⩾ 65 years, only 42% of colon cancer survivors underwent 1-year surveillance colonoscopy. Demographic and clinical factors were associated with adherence.

Pain and Distress from Bone Marrow Aspirations and Lumbar Punctures

2003 ◽  
Vol 37 (1) ◽  
pp. 17-22 ◽  
Author(s):  
Mark T Holdsworth ◽  
Dennis W Raisch ◽  
Stuart S Winter ◽  
Jami D Frost ◽  
Michele A Moro ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cohort Study ◽  
General Anesthesia ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Eutectic Mixture ◽  
Pain Scale ◽  
Emla Cream ◽  
Relieve Pain ◽  
Oral Midazolam

OBJECTIVE To compare the efficacy of 3 different pharmacologic regimens to relieve pain and distress in children with cancer undergoing bone marrow aspirations (BMAs) and lumbar punctures (LPs). DESIGN Retrospective cohort study with crossovers for some patients. PATIENTS AND METHODS The pain and distress ratings of patients undergoing BMAs (n = 73) and LPs (n = 105) were examined in a comparison of 3 different interventions: (1) a topical eutectic mixture of lidocaine and prilocaine (EMLA cream), (2) oral midazolam and EMLA cream, or (3) propofol/fentanyl general anesthesia. The choice of the intervention depended on patient/parent request. A validated faces pain scale was completed by the child or parent following each BMA or LP. The faces pain scale includes ratings of the severity of pain (from 0 = none to 5 = severe) and ratings of how frightened (from 0 = not scared to 5 = scared) the child was prior to each procedure. Comparisons of the pain and distress ratings were made among all patients for their first procedure and also within individual patients who had received >1 of the 3 interventions. Independent comparisons between the first treatments received by each patient were analyzed using Kruskal–Wallis tests. Comparisons of different crossover treatments received by individual patients were analyzed using Wilcoxon tests. RESULTS For all first procedures, mean ± SD pain and distress ratings during LPs were significantly lower when propofol/fentanyl was used (n = 43; 0.4 ± 1.0 and 1.4 ± 1.7) versus either EMLA (n = 29; 2.4 ± 1.7 and 2.9 ± 1.9) or midazolam/EMLA (n = 33; 2.4 ± 1.8 and 2.7 ± 1.8), respectively. Pain and distress ratings during BMAs were also significantly lower with propofol/fentanyl (n = 29; 0.5 ± 1.0 and 1.2 ± 1.7) versus EMLA (n = 21; 3.5 ± 1.6 and 3.3 ± 1.8) or midazolam/EMLA (n = 23; 3.3 ± 1.5 and 3.0 ± 1.9), respectively. When data were analyzed within each patient, these differences were also present. CONCLUSIONS Children receiving propofol/fentanyl general anesthesia experienced significantly less procedure-related pain and distress than did those receiving either EMLA or oral midazolam/EMLA.

Sign in / Sign up

Export Citation Format

Share Document